Arcadia Biosciences, Inc.
For the period ended Mar 31, 2026. Filed May 14, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 14, 2026
RKDA$0.17-0.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations and Comprehensive (Loss) Income
(In thousands, except share and per share data)
| Three Months Ended March 31, | ||
|---|---|---|
| 2026 | 2025 | |
| Revenues: | ||
| Product | $1,100 | $1,200 |
| Total revenues | 1,100 | 1,200 |
| Operating expenses (income): | ||
| Cost of revenues | 700 | 682 |
| Gain on sale of intangible assets | — | (750) |
| Change in fair value of contingent consideration | — | (1,000) |
| Selling, general and administrative | 1,179 | 1,738 |
| Total operating expenses | 1,879 | 670 |
| (Loss) Income from continuing operations | (779) | 530 |
| Interest income | 5 | 207 |
| Other loss, net | (1,504) | — |
| Loss on January 2026 Inducement Offer | (2,877) | — |
| Change in fair value of common stock warrant and option liabilities | 1,191 | 1,862 |
| Issuance and offering costs | (421) | — |
| Net (loss) income attributable to common stockholders | $(4,385) | $2,599 |
| Net (loss) income per share attributable to common stockholders: | ||
| Basic | $(2.11) | $1.90 |
| Diluted | $(2.11) | $1.90 |
| Weighted-average number of shares used in per share calculations: | ||
| Basic | 2,082,887 | 1,366,060 |
| Diluted | 2,082,887 | 1,366,203 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.